A Phase I Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-6208 Monotherapy in Patients With Advanced Solid Tumors
Latest Information Update: 17 Dec 2024
Price :
$35 *
At a glance
- Drugs HRS 6208 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Shandong Suncadia Medicine
- 17 Dec 2024 New trial record